Wytyczne dla autorów




NOWOTWORY Journal of Oncology publishes papers which cover all aspects of oncology but concentrates on clinical studies, both research orientated and treatment orientated, rather than on laboratory studies. Contributions are also welcomed from the fields of epidemiology, tumor pathology, radiobiology and radiation physics.

Journal follows editorial recommendations of International Committee of Medical Journal Editors (ICMJE) (available at http://www.icmje.org/recommendations/). Via Medica strongly recommends journal editors to adhere to the principles of Committee on Publication Ethics (COPE), particularly to deal with acts of ethical misconduct. For more information Authors, Readers and Editors may visit the COPE website: http://publicationethics.org/.

Authors statment All submitted manuscripts will be peer reviewed and the authors will be required to state that their paper has not been previously published or has been accepted for publication elsewhere, and has not simultaneously been submitted to another journal. An author statment must accompany each submitted manuscript and this letter must be signed by all authors and not only by the first author. In this letter any financial conflicts of interest must be specified. In addition, all sources of financial support for the study must be described. It is the responsibility of the main author of the paper to obtain written copyright permission for any material, text or illustrations, for which the copyright is owned by another person or persons or by an organization or by another journal. By submitting all the materials included in the submission authors declare that they poses non limited rights to use all the materials in the printed version of their submission.

Publication ethics and malpractice statement The Editor is responsible for everything published in the journal. The Editor takes all reasonable steps to ensure the quality of the material published. The Editor’s decision to accept or reject a paper for publication is based only on the paper’s importance, originality, clarity and the study’s relevance to the remit of the journal. The description of peer review process is published and clarified and the Editor is able and ready to justify any important deviation from the described process. The authors and peer reviewers’ identities are protected. The Editor provides guidance to authors and reviewers on everything that is expected of them. The Editor does not reverse a decision to accept a submission unless serious problems are identified. The relationship of the Editor to the publisher and owner is based firmly on the principle of editorial independence. The Editor makes decisions on which articles to publish based on quality and suitability for the journal and without interference from the journal owner/publisher.
The Editor can ensure that research material they publish conforms to internationally accepted ethical guidelines. The Editor is able to protect the confidentiality of individual information. The Editor has a duty to act if they suspect misconduct. The duty extends to both published and unpublished papers. The Editor should seek a response from those accused. If not satisfied with the response, the Editor should ask the relevant employers or some appropriate body to investigate. Editors should have systems for managing their own conflicts of interest as well as those of their staff, authors, reviewers and Editorial board members.

Human participants rights Any papers submitted which have required approval by local Ethics Committee, whether this be with regard to cancer patients within randomized or non-randomized clinical trials/studies or with regard to animal experimentation, should contain a statement to the effect that such approval has been obtained. In addition, written consent should be obtained for publication of any data or photograph, that might identify an individual patient. All procedures should be in accordance with the Helsinki Declaration.

Technical requirements for manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals prepared by the International Committee of Medical Journal Editors (the Vancouver style) — see N Eng J Med 1997; 336: 309–315 or Nowotwory 2000; 50: 64–68.

Text The editors of "Nowotwory. Journal of Oncology" make every effort to carry out the evaluation and publication of submitted articles as soon as possible. All articles with figures, tables and supplementary files should be submitted by the electronic manuscript service system at https://journals.viamedica.pl/nowotwory_journal_of_oncology

Articles submitted to Nowotwory Journal of Oncology should be written in English and strictly follow journal requirements available on journal’s website.

Submissions in Polish will only be accepted after prior consent of the editor – please contact editorial office for approval before submission.

The contents must be clear, accurate, coherent and logical. The text of the original paper should be divided into the following sections: Introduction, Material and Methods, Results, Discussion and Conclusions. Abbreviations which are not generally accepted, should be explained when first used in the text. Footnotes should be avoided wherever possible and no paper should contain more than two footnotes.

Types of manuscripts accepted


Words limit*

References limit*

Figures and Tables limit*

Original articles








Pictures in Oncology




Letters to Editor




Other types of manuscripts

as agreed before submission with the editor – please contact editorial office

Title page. Should contain the title, the names of all authors, the name of institution to which the article should be attributed, the name, postal and e-mail address of the corresponding author. Authorship requires substantial contributions to the development of the concept of the paper, the analysis and interpretation of data and the drafting and revision of manuscript submissions. Up to 5 key words should be supplied, using terms from the medical subject headings (MeSH) list of Index Medicus.

There is a limit of up to 4 authors in Pictures in Oncology articles, with no exceptions.

An abstract not exceeding 150 words should be presented on a separate sheet. Abstracts of original papers should be divided into the following sections: Introduction, Material and Methods, Results, Discussion, Conclusions.

Statistics. Statistical methods must be identified and described in sufficient detail for a knowledgeable reader to be able to reproduce the statistical analysis when provided with access to the raw data. When appropriate, statistical levels of significance should be quoted, e.g. p < 0.05.

Tables. Each table should be typed double spaced on a separate sheet and must have a fully explanatory title. All tables should be numbered in order of appearance and referred to by number in the text. Place explanatory matter in notes beneath the table, not in the table legend. Tables must be numbered using Roman numerals.

Illustrations. They should be numbered consecutively and be cited in the text. Descriptive legends for the figures should be typed in a separate list. Computer-drawn figures can be accepted only if they are of good quality. If authors wish to have their illustrations published in color, they must communicate that desire when the manuscript is submitted. The cost of color illustrations can be charged to the authors. Figures must be supplied electronically, e.g. tiff files.

References. References must be cited as numerals in brackets in order in which they are first mentioned in the text. The titles of journals should be abbreviated according to the style used in Index Medicus. List all the authors if a paper has three or fewer authors. For more than three authors list only the first three authors followed by et al. Follow the correct style of citing references in biomedical publications prepared by the International Committee of Medical Journal Editors — see N Eng J Med 1997; 336: 309–315 or Nowotwory 1997; 47: 403–406. Note the following examples:

Journal articles: Parkin D, Clayton P, Black RF et al. Childhood leukaemia in Europe after Chernobyl. Br J Cancer 1996; 73: 1006–1012.

Please add DOI wherever possible!

Chapter in a book: Philips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, (eds.) Hypertension: pathophysiology diagnosis and management. Ed. 2. New York: Raven Press; 1995, p. 465–478.

Proceedings: Bengtsson S, Solheim Bo. Enforcement of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, (eds.). MEDINFO 92. Proceedings of the 7th World Congress on Medical Informatics; 6–10 Sept. 1992; Geneva, Switzerland. Amsterdam: North-Holland; 1992, p. 1561–1565.

Oświadczenie autorów

Informacje o prawach autorskich

Wypełniając formularz zgłoszeniowy na stronie www, autorzy oświadczają, że automatycznie i nieodpłatnie przenoszą na Polskie Towarzystwo Onkologiczne (PTO) całość praw autorskich i praw zależnych do wydawania i rozpowszechniania nadesłanych materiałów we wszystkich znanych i mogących powstać w przyszłości formach wydawniczych lub do innego sposobu rozpowszechniania pracy oraz na wszystkich znanych i mogących powstać w przyszłości polach eksploatacji — pod warunkiem, że praca ta została zaakceptowana do publikacji i opublikowana. Jednocześnie autorzy zgadzają się, że nie złożą manuskryptu do publikacji gdziekolwiek i w jakimkolwiek języku bez wcześniejszej pisemnej zgody nabywcy praw autorskich, jakim jest Polskie Towarzystwo Onkologiczne (PTO).

Wszelkie ewentualne spory dotyczące publikacji rozstrzygane będą przez Sąd Rejonowy właściwy dla siedziby Wydawnictwa. Stosunki prawne łączące Wydawnictwo i autora podlegają prawu polskiemu i obowiązującym Polskę konwencjom międzynarodowym. Podstawą prawną nabycia praw autorskich jest art. 921 § 3 zdanie 3. kodeksu cywilnego w związku z art. 50 ustawy o prawie autorskim i prawach pokrewnych i odpowiednich konwencji międzynarodowych.

Polityka prywatności
Nazwiska i adresy e-mail wprowadzane do serwisu tego czasopisma będą wykorzystywane wyłącznie do wyżej wymienionych celów i nie będą udostępniane do innych celów.

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory